437 related articles for article (PubMed ID: 18989850)
1. Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds.
Fura A; Vyas V; Humphreys W; Chimalokonda A; Rodrigues D
Biopharm Drug Dispos; 2008 Nov; 29(8):455-68. PubMed ID: 18989850
[TBL] [Abstract][Full Text] [Related]
2. Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
Bae SK; Lee SJ; Kim YG; Kim SH; Kim JW; Kim T; Lee MG
Biopharm Drug Dispos; 2005 Apr; 26(3):99-115. PubMed ID: 15723427
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE
Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721
[TBL] [Abstract][Full Text] [Related]
4. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach.
Izumi T; Enomoto S; Hosiyama K; Sasahara K; Shibukawa A; Nakagawa T; Sugiyama Y
J Pharmacol Exp Ther; 1996 Jun; 277(3):1630-41. PubMed ID: 8667232
[TBL] [Abstract][Full Text] [Related]
5. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
7. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
[TBL] [Abstract][Full Text] [Related]
8. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
Hosea NA; Collard WT; Cole S; Maurer TS; Fang RX; Jones H; Kakar SM; Nakai Y; Smith BJ; Webster R; Beaumont K
J Clin Pharmacol; 2009 May; 49(5):513-33. PubMed ID: 19299532
[TBL] [Abstract][Full Text] [Related]
9. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs.
De Buck SS; Sinha VK; Fenu LA; Nijsen MJ; Mackie CE; Gilissen RA
Drug Metab Dispos; 2007 Oct; 35(10):1766-80. PubMed ID: 17620347
[TBL] [Abstract][Full Text] [Related]
10. Interspecies scaling of the pharmacokinetics of N-nitrosodimethylamine.
Gombar CT; Harrington GW; Pylypiw HM; Anderson LM; Palmer AE; Rice JM; Magee PN; Burak ES
Cancer Res; 1990 Jul; 50(14):4366-70. PubMed ID: 2364390
[TBL] [Abstract][Full Text] [Related]
11. Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.
Sinha VK; Vaarties K; De Buck SS; Fenu LA; Nijsen M; Gilissen RA; Sanderson W; Van Uytsel K; Hoeben E; Van Peer A; Mackie CE; Smit JW
Clin Pharmacokinet; 2011 May; 50(5):307-18. PubMed ID: 21456631
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Human Pharmacokinetics of Ulixertinib, a Novel ERK1/2 Inhibitor from Mice, Rats, and Dogs Pharmacokinetics.
Suresh PS; Jairam RK; Chandrasekhar DV; Vinod AB; Hiremath RA; Raj A; Zainuddin M; Bhamidipati RK; Mullangi R
Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):453-460. PubMed ID: 29470718
[TBL] [Abstract][Full Text] [Related]
13. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
[TBL] [Abstract][Full Text] [Related]
14. The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies.
Cheung BW; Cartier LL; Russlie HQ; Sawchuk RJ
Fundam Clin Pharmacol; 2005 Jun; 19(3):347-54. PubMed ID: 15910659
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of terbutaline after parenteral administration.
Fagerström PO
Eur J Respir Dis Suppl; 1984; 134():101-10. PubMed ID: 6586470
[TBL] [Abstract][Full Text] [Related]
16. Comparative kinetics of sematilide in four species.
Hinderling PH; Dilea C; Koziol T; Millington G
Drug Metab Dispos; 1993; 21(4):662-9. PubMed ID: 8104126
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of buprenorphine following intravenous administration in dogs.
Krotscheck U; Boothe DM; Little AA
Am J Vet Res; 2008 Jun; 69(6):722-7. PubMed ID: 18518651
[TBL] [Abstract][Full Text] [Related]
18. Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs.
Boothe DM; Perkins J
J Vet Pharmacol Ther; 2008 Dec; 31(6):544-53. PubMed ID: 19000278
[TBL] [Abstract][Full Text] [Related]
19. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.
Obach RS; Baxter JG; Liston TE; Silber BM; Jones BC; MacIntyre F; Rance DJ; Wastall P
J Pharmacol Exp Ther; 1997 Oct; 283(1):46-58. PubMed ID: 9336307
[TBL] [Abstract][Full Text] [Related]
20. Interspecies pharmacokinetic scaling of DA-8159, a new erectogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
Shim HJ; Kim YC; Lee JH; Kwon JW; Kim WB; Kim YG; Kim SH; Lee MG
Biopharm Drug Dispos; 2005 Oct; 26(7):269-77. PubMed ID: 15991256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
